Lovenox Articles

Court rules in novel False Claims Act case where one pharma firm sues another viewed by HP&M lawyer

28 April 2013

Watson settles over Exalgo; gets favorable news on enoxaparin

29 January 2012

Watson temporarily restrained from marketing generic Lovenox; challenges Pfizer’s Embeda patent

10 October 2011

Sanofi prevails over Sun Pharma in Eloxatin patent suit; another generic Lovenox approved

20 September 2011

US Senators accuse Sanofi over lobbying FDA on generic Lovenox

26 May 2011

Sanofi-Aventis' Lovenox favored by US medics for VTE primary prophylaxis

24 March 2011

US FDA issues action letter for Teva’s generic Lovenox; grants orphan status for BioSante vaccine

26 January 2011

Amphastar files Amended Complaint against US FDA over Lovenox

5 January 2011

Momenta Pharma sues Teva for enoxaparin patent infringement

3 December 2010

26 August 2010

Sanofi-Aventis 2nd-qtr 2010 earnings up 8%, but firm still mute on Genzyme acquisition; sues over Lovenox

29 July 2010

US FDA approves first generic of Sanofi-Aventis’ Lovenox for Sandoz, for DVT prevention

26 July 2010

US survey reveals need to better balance effects and cost of therapeutic drug use in the hospital

25 June 2010

Sanofi-Aventis 2009 EPS leaps 18% but slows in 4th quarter; in line with expectations

10 February 2010

Generic erosion will bite into the acute coronary syndrome market, cutting sales nearly 10% from 2008 to 2018

8 December 2009

Sanofi-Aventis says strong swine flu vaccine sales in 4th quarter will drive higher earnings

30 October 2009

US CDER chief under investigation over conflict of interest

13 September 2009

Sanofi loses appeal over Lovenox patent

30 April 2009

Sanofi sees rising sales in first-quarter 2009 as Zentiva acquisition pays off

29 April 2009

Stock Commentary - Europe - week to March 23, 2009

30 March 2009

Bayer rises 9% as FDA panel recommends Xarelto for post-surgery VTE prevention

30 March 2009

Bayer drops 10% ahead of rivaroxaban review

23 March 2009

Momenta could be first to benefit from Obama plan to push for biogenerics

23 March 2009

NICE gives nod to Bayer's Xarelto

16 March 2009

Sanofi-Aventis' 4th-qtr adjusted net leaps 13,9%, on older drug sales growth

16 February 2009

US Court dismisses whistleblower case against drugmaker

19 January 2009

ASH hears strong data on Novartis

22 December 2008

Pooled RECORD data "confirm Xarelto better than Lovenox"

15 December 2008

Sales of main products boosts Sanofi-Aventis' profit 1.9% to 1.89B euros

10 November 2008

Bayer gets European approval for Xarelto

6 October 2008

Health Canada gives Bayer's Xarelto first ever approval for VTE after surgery

22 September 2008

Sanofi-Aventis' second-quarter 2008 results disappoint analysts, hit by weak US dollar

11 August 2008

Bayer/J&J's Xarelto gets nod from CHMP

4 August 2008

Rivaroxaban beats Lovenox: RECORD4 trial

16 June 2008

Bayer's Xarelto wins out in study

9 June 2008

Big patent decisions on Lovenox and Lipitor

2 June 2008

US Federal Court denies Sanofi-Aventis

19 May 2008

UPDATE: Sanofi falls 6% on news of EU generic Plavix, but it may not be substitutable

19 May 2008

Sanofi-Aventis

5 May 2008

China denies heparin contamination

28 April 2008

Spiriva and Micardis boost Boehringer's 2007 sales 8.8%, as profit jumps 4.8% to $2.8M

14 April 2008

Momenta Pharma sets priority on launch of M-Enoxaparin, as losses narrow

7 April 2008

EC approves Boeh Ing's Pradaxa in VTE

7 April 2008

Sanofi-Aventis' "insulin city" and SoloSTAR investments paying dividends

25 February 2008

Sanofi-Aventis 2007 profits rise a modest 1%; sales impacted by exchange rates

18 February 2008

Clexane, and Nexavar in RCC approved in Japan

4 February 2008

UPDATE: Sanofi-Aventis to invest 100 million euros in new Chinese flu vaccine facility

3 December 2007

Stock Commentary - Europe - week to Nov 12, 2007

19 November 2007

Sanofi-Aventis sees 9% rise in third-quarter profit, beating forecasts

5 November 2007

Angiox impresses in ACS patients undergoing PCI

10 September 2007

Sanofi's Lovenox shows benefit in STEMI

10 September 2007

Sanofi-Aventis 2nd-qtr profit falls as generics take toll on Eloxati and Ambien

6 August 2007

Boeh Ing's dabigatran as effective as enoxaparin

16 July 2007

Prophylactic Lovenox cuts VTE risk 44%

16 July 2007

UPDATE: Bayer's rivaroxaban shows superiority to enoxaparin in Ph III

16 July 2007

Bayer to present strong data on rivaroxaban at ISTH meeting

16 July 2007

FDA approves Lovenox sNDA for STEMI

28 May 2007

Generics and currencies impact Sanofi-Aventis' 1st-qtr, with income down 2.26%

14 May 2007

Clexane more effective than UFH in VTE

30 April 2007

Stock Commentary - Europe - week to Feb 12, 2007

19 February 2007

Sanofi-Aventis pressured by US Plavix generic and European health reforms

19 February 2007

Sanofi-Aventis' 4th-qtr profit falls 4.6%

19 February 2007

Sanofi-Aventis loses US Lovenox patent case

19 February 2007

FDA priority review for Sanofi's Lovenox in STEMI

12 February 2007

Sanofi-Aventis' enoxaparin cuts VTE risk 43%

18 December 2006

Generics, including Plavix, and govt cost-cutting hit Sanofi-Aventis' 3rd-qtr results

6 November 2006

GSK's Arixtra gets fast tracked by US FDA

16 October 2006

Sanofi's Lovenox: less bleeds than heparin

18 September 2006

Vaccines boost Sanofi-Aventis 1st-half but French/German reforms hit drug sales

7 August 2006

Sandoz and Momenta to collaborate on generics R&D

31 July 2006

Enoxaparin results in cost savings compared with UFH in VTE

3 July 2006

Sanofi-Aventis beats expectations with 1st-qtr adjusted EPS rising 53%

15 May 2006

GSK's Arixtra comparable to Sanofi-Aventis's Lovenox in trials

17 April 2006

Sanofi-Aventis wins Lovenox patent appeal

17 April 2006

Lovenox superior to heparin in cardio study

20 March 2006

Sanofi-Aventis sales slow on competition

6 February 2006

Bayer to pay up to $385M for ex-US sale rights to Nuvelo's Ph III thrombolytic, alfimeprase

16 January 2006

Momenta files ANDA for M-Enoxaparin

5 September 2005

Sanofi-Aventis: is growth slowing?

1 August 2005

Strong 2nd qtr for Sanofi-Aventis

25 July 2005

Studies indicate Bayer's BAY 59-739 is as safe and effective as Lovenox for VTE

25 July 2005

Stock Commentary - European

27 June 2005

Problems for Sanofi on Lovenox ruling

27 June 2005

Sanofi loses 1st round in Lovenox patent battle

27 June 2005

R&M releases new report on blockbusters

30 May 2005

Sanofi-Aventis beats world market growth with 1st-qtr sales up 11.9%

23 May 2005

UPDATE: Sanofi-Aventis reports forecast-beating earnings, 1st-qtr sales up 11.9%

23 May 2005

French patent expiries to save1B euros by 2008

23 May 2005

Sanofi-Aventis sues Novopharm over patent

21 March 2005

Sanofi-Aventis 2004 sales rise 10%

31 January 2005

USPTO approves Sanofi-Aventis Lovenox patent renewal

10 January 2005

Sanofi-Aventis scoops marketing awards

20 December 2004

US patent challenge for Sanofi-Aventis' Plavix - the risks from Canada

15 November 2004

Sanofi-Aventis' 3rd-qtr sales rise 10.7%

1 November 2004

PCAS expands deal with Sanofi-Aventis

25 October 2004

MS initiates coverage of newly-formed Sanofi-Aventis with overweight rating

13 September 2004

Aventis committed to reissuance process for Lovenox patent

9 August 2004

Sanofi to sell Aventis' Campto to Pfizer

5 July 2004

French govt pressure and increased offer push Aventis into marriage with Sanofi

3 May 2004

New data for Aventis' Lovenox

22 March 2004